Glycation of Plasma Lipoprotein Lipid Membrane and Screening for Lipid Glycation Inhibitor

2008 ◽  
Vol 1126 (1) ◽  
pp. 288-290 ◽  
Author(s):  
Kiyotaka Nakagawa ◽  
Daigo Ibusuki ◽  
Shinji Yamashita ◽  
Teruo Miyazawa
Keyword(s):  
Lipid Membrane ◽  
Plasma Lipoprotein ◽  
Lipoprotein Lipid ◽  
Lipid Glycation

scholarly journals Plasma lipoprotein lipid and Lp[a] changes with substitution of elaidic acid for oleic acid in the diet.

1992 ◽  
Vol 33 (7) ◽  
pp. 1029-1036
Author(s):  
P Nestel ◽  
M Noakes ◽  
B Belling ◽  
R McArthur ◽  
P Clifton ◽  
...  
Keyword(s):  
Oleic Acid ◽  
Elaidic Acid ◽  
Plasma Lipoprotein ◽  
Lipoprotein Lipid

scholarly journals Plasma Lipoprotein Distribution of Liposomal Nystatin Is Influenced by Protein Content of High-Density Lipoproteins

1998 ◽  
Vol 42 (8) ◽  
pp. 1878-1888 ◽  
Author(s):  
Shawn M. Cassidy ◽  
Frank W. Strobel ◽  
Kishor M. Wasan
Keyword(s):  
Human Plasma ◽  
Protein Concentration ◽  
Density Lipoprotein ◽  
High Density ◽  
Plasma Lipoprotein ◽  
High Density Lipoproteins ◽  
Plasma Samples ◽  
Lipoprotein Lipid ◽  
Plasma Fractions ◽  
Lipoprotein Distribution

ABSTRACT The plasma lipoprotein distribution of free nystatin (Nys) and liposomal nystatin (L-Nys) in human plasma samples with various lipoprotein lipid and protein concentrations and compositions was investigated. To assess the lipoprotein distributions of Nys and L-Nys, human plasma was incubated with Nys and L-Nys (equivalent to 20 μg/ml) for 5 min at 37°C. The plasma was subsequently partitioned into its lipoprotein and lipoprotein-deficient plasma fractions by step-gradient ultracentrifugation, and each fraction was analyzed for Nys content by high-pressure liquid chromatography. The lipid and protein contents and compositions of each fraction were determined with enzymatic kits. Following the incubation of Nys and L-Nys in human plasma the majority of Nys recovered within the lipoprotein fractions was recovered from the high-density lipoprotein (HDL) fraction. Incorporation of Nys into liposomes consisting of dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol significantly increased the percentage of drug recovered within the HDL fraction. Furthermore, it was observed that as the amount of HDL protein decreased the amounts of Nys and L-Nys recovered within this fraction decreased. These findings suggest that the preferential distribution of Nys and L-Nys into plasma HDL may be a function of the HDL protein concentration.

APO E gene and gene-environment effects on plasma lipoprotein-lipid levels

2000 ◽  
Vol 4 (2) ◽  
pp. 101-108 ◽  
Author(s):  
JAMES M. HAGBERG ◽  
KENNETH R. WILUND ◽  
ROBERT E. FERRELL
Keyword(s):  
Ldl Cholesterol ◽  
Disease Risk ◽  
Strong Support ◽  
Lipid Profiles ◽  
Plasma Lipoprotein ◽  
The Other ◽  
Cholesterol Levels ◽  
Lipoprotein Lipid ◽  
Other Hand ◽  
Apo E

Apolipoprotein E (apo E) is important in plasma lipid metabolism and is a component of several plasma lipoprotein-lipid particles. Three major apo E isoforms are encoded by three common alleles at the APO E locus. The E2 allele is associated with lower and the E4 allele with higher total plasma cholesterol and LDL cholesterol levels compared with the E3 allele. Available data generally indicate that APO E2, and possibly E3, genotype individuals reduce plasma total and low-density lipoprotein (LDL) cholesterol levels more than APO E4 individuals with statin therapy. Some evidence also indicates that APO E2 individuals are more likely to respond favorably to gemfibrozil and cholestyramine. On the other hand, it appears that with probucol, APO E4 genotype individuals may improve plasma lipoprotein-lipid profiles more than APO E3 individuals. APO E2 and E3 genotype perimenopausal women appear to improve plasma lipoprotein-lipid profiles more with hormone replacement therapy than APO E4 women. On the other hand, low-fat diet interventions tend to reduce plasma LDL cholesterol and, perhaps, plasma total cholesterol levels more in APO E4 than in APO E2 or E3 individuals. Both cross-sectional and longitudinal studies generally indicate that APO E2 and E3 individuals improve plasma lipoprotein-lipid profiles more with exercise training than APO E4 individuals. Although these data are hardly definitive, they lend strong support for the possibility that in the near future individuals will be directed to what might be their optimal therapy for improving plasma lipoprotein-lipid profiles and cardiovascular disease risk based partially on APO E genotype.

Apolipoprotein E polymorphism and the relationships of physical fitness to plasma lipoprotein-lipid levels in men and women

1999 ◽  
Vol 31 (5) ◽  
pp. 692-697 ◽  
Author(s):  
JONNY ST.-AMAND ◽  
DENIS PRUD'HOMME ◽  
SITAL MOORJANI ◽  
ANDR?? NADEAU ◽  
ANGELO TREMBLAY ◽  
...  
Keyword(s):  
Physical Fitness ◽  
Apolipoprotein E ◽  
Plasma Lipoprotein ◽  
Lipid Levels ◽  
Men And Women ◽  
Lipoprotein Lipid ◽  
Apolipoprotein E Polymorphism

COMMON GENETIC POLYMORPHISMS AND PLASMA LIPOPROTEIN LIPID RESPONSES TO EXERCISE TRAINING

2002 ◽  
Vol 34 (5) ◽  
pp. S189
Author(s):  
A Halverstadt ◽  
R E. Ferrell ◽  
L Douglass ◽  
A P. Goldberg ◽  
D A. Phares ◽  
...  
Keyword(s):  
Exercise Training ◽  
Genetic Polymorphisms ◽  
Plasma Lipoprotein ◽  
Lipoprotein Lipid

scholarly journals Species Differences in the Proportion of Plasma Lipoprotein Lipid Carried by High-Density Lipoproteins Influence the Distribution of Free and Liposomal Nystatin in Human, Dog, and Rat Plasma

1999 ◽  
Vol 43 (6) ◽  
pp. 1424-1428 ◽  
Author(s):  
Manisha Ramaswamy ◽  
Thomas L. Wallace ◽  
Paul A. Cossum ◽  
Kishor M. Wasan
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Rat Plasma ◽  
High Density ◽  
Plasma Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Plasma Lipoproteins ◽  
High Density Lipoproteins ◽  
Lipoprotein Lipid ◽  
Triglyceride Rich Lipoprotein

ABSTRACT The objective of this study was an interspecies comparison of free nystatin (NYS) and liposomal NYS (Nyotran) distribution in plasma. NYS and liposomal NYS at concentrations of 5, 10, and 20 μg of NYS/ml were incubated in human, dog, and rat plasma for 5, 60, and 180 min at 37°C. Following these incubations, plasma samples were separated into their high-density lipoprotein (HDL), triglyceride-rich lipoprotein, low-density lipoprotein, and lipoprotein-deficient plasma (LPDP) fractions by density-gradient ultracentrifugation, and each fraction was assayed for NYS by high-pressure liquid chromatography. Total plasma and lipoprotein cholesterol, triglyceride, and protein concentrations in each human, dog, or rat plasma sample were determined by enzymatic assays. When NYS and liposomal NYS were incubated in human, dog, or rat plasma, the majority of the NYS was recovered in the LPDP fraction. For the 5- and 60-min incubation times for all plasmas measured, a significantly greater percentage of NYS was recovered in the lipoprotein fraction (primarily HDL) following the incubation of liposomal NYS than following the incubation of NYS. There was a significant correlation between the lipoprotein lipid and protein profiles in human, dog, and rat plasmas and the distribution of NYS and liposomal NYS in plasma. In particular, differences in the proportion of plasma lipoprotein cholesterol, triglyceride, and apolar lipids (cholesteryl ester and triglycerides) carried by HDL influenced the distribution of NYS and liposomal NYS within plasmas of different species. These findings suggest that the distribution of NYS among plasma lipoproteins of different species is defined by the proportion of lipid carried by HDL, and this is possibly an important consideration when evaluating the pharmacokinetics, toxicities, and activities of these compounds following administration to different animal species.

Sign in / Sign up

Export Citation Format

Share Document